Just Wondering II Hey Red,
I don’t think we’d be changing the "auction effect” of Pharma’s eventual offers (plural) if it was announced that a compensatory aspect to these new collaborations existed. Something along the lines of “there is a net positive valuation to the company, as a result of these collaboration agreements” if that is the case. That shows nothing to potential suitors, and does provide material information to investors (legacy and potential) now. I’m not sure who vets these NR’s that I think Dominic writes, and maybe the nature of these collaborations does not include either a cost or profit to SVA shareholders. But as a shareholder who has a history with the share value behaviour post announcements, I think there is info that can be provided that doesn’t risk company strategy, while coloring in some of the money-in, money-out piece.
As far as Rixpix observation goes, the (eventual) announcement that insulin free and anti-rejection free have both been confirmed, across patients, may or may not happen after a take out offer has been submitted. Again, the board’s responsibility to shareholders is to get full valuation for our patience. And the take out bids will be much higher if both the current study and these new collaborations prove the islets work and there is no need for anti-rejection drugs. The rest is just filler which won’t boost the daily price variations very much. I just don't want to try and time that "windfall" announcement.
DF